Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention
Background Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS‐TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (...
Gespeichert in:
| Veröffentlicht in: | Thoracic cancer 2018-11, Vol.9 (11), p.1390-1397 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1397 |
|---|---|
| container_issue | 11 |
| container_start_page | 1390 |
| container_title | Thoracic cancer |
| container_volume | 9 |
| creator | Gil, Hyun‐Il Choe, Junsu Jeong, Byeong‐Ho Um, Sang‐Won Jeon, Kyeongman Hahn, Joo‐Yong Kim, Hojoong Kwon, O Jung Chang, Yoon Soo Lee, Kyungjong |
| description | Background
Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS‐TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS‐TBNA in patients with lung cancer who underwent PCI within one year.
Methods
We retrospectively reviewed the medical records of 24 patients who underwent EBUS‐TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural‐related complications were assessed as secondary outcomes.
Results
The coronary artery diseases requiring PCI were: myocardial infarction (n = 10), unstable angina (n = 10), stable angina (n = 2), and silent ischemia (n = 2). The median interval between PCI and EBUS‐TBNA was 125 days (interquartile range: 66–180). Atrial fibrillation with a rapid ventricular response temporarily occurred in one patient after EBUS‐TBNA. No other significant cardiovascular complications were encountered. Fifteen patients were administered an anti‐thrombotic agent the day of EBUS‐TBNA, while four had ceased taking the agent < 4 days before EBUS‐TBNA, however, there was no significant bleeding among those patients.
Conclusion
EBUS‐TBNA was safe and did not cause serious adverse events in patients with lung cancer who required tissue confirmation or mediastinal staging within one year after PCI. Incidental lung cancer found during or after a coronary intervention should be actively evaluated by EBUS‐TBNA. |
| doi_str_mv | 10.1111/1759-7714.12846 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6209775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737059210</galeid><sourcerecordid>A737059210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5346-60ff54e9fee065ec6ba3ead00b78222aeaf50cbf4f20c750b52c878cdb386ad73</originalsourceid><addsrcrecordid>eNqFksFu1DAQQCMEolXpmRuyxIXLbh0ntpML0mpVClIlDpSz5djjXVdZe7GTVnvjE_gEvq1fwmxTthQh4Rxsjd-8yVhTFK9LOi9xnZWStzMpy3pesqYWz4rjQ-T54UzFUXGa8zXFVTUtZfxlcVTRkouqocfFzy_awbAj0REINnYpBrP2uidjPySd4xjs3fcfq9FbsAQjIT8iAcD2QHTe-qQHHwPxgWzxBGHI5NYPa9KPYUWMDgbSfQABTXagE9FuwNgWkhkHHSCOmZiIap12qMG7G7Sg81Xxwuk-w-nDflJ8_XB-tfw4u_x88Wm5uJwZXtViJqhzvIbWAVDBwYhOV6AtpZ1sGGMatOPUdK52jBrJaceZaWRjbFc1QltZnRTvJ-927DZgDVZPulfb5Df4Sypqr57eBL9Wq3ijBKOtlBwF7x4EKX4bIQ9q47OBvp-6U4gJzllZN4i-_Qu9jmMK2J5irG0l-trqkVrpHpQPLmJds5eqhawk5S0rKVLzf1D4Wdh4EwM4j_EnCWdTgkkx5wTu0GNJ1X6u1H5y1H6K1P1cYcabP5_mwP-eIgT4BNxird3_fOpquZjEvwCmW90F</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299797793</pqid></control><display><type>article</type><title>Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Gil, Hyun‐Il ; Choe, Junsu ; Jeong, Byeong‐Ho ; Um, Sang‐Won ; Jeon, Kyeongman ; Hahn, Joo‐Yong ; Kim, Hojoong ; Kwon, O Jung ; Chang, Yoon Soo ; Lee, Kyungjong</creator><creatorcontrib>Gil, Hyun‐Il ; Choe, Junsu ; Jeong, Byeong‐Ho ; Um, Sang‐Won ; Jeon, Kyeongman ; Hahn, Joo‐Yong ; Kim, Hojoong ; Kwon, O Jung ; Chang, Yoon Soo ; Lee, Kyungjong</creatorcontrib><description>Background
Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS‐TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS‐TBNA in patients with lung cancer who underwent PCI within one year.
Methods
We retrospectively reviewed the medical records of 24 patients who underwent EBUS‐TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural‐related complications were assessed as secondary outcomes.
Results
The coronary artery diseases requiring PCI were: myocardial infarction (n = 10), unstable angina (n = 10), stable angina (n = 2), and silent ischemia (n = 2). The median interval between PCI and EBUS‐TBNA was 125 days (interquartile range: 66–180). Atrial fibrillation with a rapid ventricular response temporarily occurred in one patient after EBUS‐TBNA. No other significant cardiovascular complications were encountered. Fifteen patients were administered an anti‐thrombotic agent the day of EBUS‐TBNA, while four had ceased taking the agent < 4 days before EBUS‐TBNA, however, there was no significant bleeding among those patients.
Conclusion
EBUS‐TBNA was safe and did not cause serious adverse events in patients with lung cancer who required tissue confirmation or mediastinal staging within one year after PCI. Incidental lung cancer found during or after a coronary intervention should be actively evaluated by EBUS‐TBNA.</description><identifier>ISSN: 1759-7706</identifier><identifier>EISSN: 1759-7714</identifier><identifier>DOI: 10.1111/1759-7714.12846</identifier><identifier>PMID: 30156380</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Aged ; Angioplasty ; Blood pressure ; Bronchoscopy ; Cardiac arrhythmia ; Cardiology ; Cardiovascular disease ; Care and treatment ; Clopidogrel ; Coronary vessels ; Endoscopic Ultrasound-Guided Fine Needle Aspiration - methods ; endoscopic ultrasound‐guided fine needle aspiration ; Female ; Heart attack ; Heart diseases ; Humans ; Lung cancer ; lung neoplasm ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Middle Aged ; neoplasm staging ; Original ; Patients ; percutaneous coronary intervention ; Percutaneous Coronary Intervention - methods ; Retrospective Studies ; Safety and security measures ; Stents ; Studies ; Tomography ; Transluminal angioplasty ; Ultrasonic imaging</subject><ispartof>Thoracic cancer, 2018-11, Vol.9 (11), p.1390-1397</ispartof><rights>2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd</rights><rights>2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.</rights><rights>COPYRIGHT 2018 John Wiley & Sons, Inc.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5346-60ff54e9fee065ec6ba3ead00b78222aeaf50cbf4f20c750b52c878cdb386ad73</citedby><cites>FETCH-LOGICAL-c5346-60ff54e9fee065ec6ba3ead00b78222aeaf50cbf4f20c750b52c878cdb386ad73</cites><orcidid>0000-0002-1642-8111</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209775/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209775/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30156380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gil, Hyun‐Il</creatorcontrib><creatorcontrib>Choe, Junsu</creatorcontrib><creatorcontrib>Jeong, Byeong‐Ho</creatorcontrib><creatorcontrib>Um, Sang‐Won</creatorcontrib><creatorcontrib>Jeon, Kyeongman</creatorcontrib><creatorcontrib>Hahn, Joo‐Yong</creatorcontrib><creatorcontrib>Kim, Hojoong</creatorcontrib><creatorcontrib>Kwon, O Jung</creatorcontrib><creatorcontrib>Chang, Yoon Soo</creatorcontrib><creatorcontrib>Lee, Kyungjong</creatorcontrib><title>Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention</title><title>Thoracic cancer</title><addtitle>Thorac Cancer</addtitle><description>Background
Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS‐TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS‐TBNA in patients with lung cancer who underwent PCI within one year.
Methods
We retrospectively reviewed the medical records of 24 patients who underwent EBUS‐TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural‐related complications were assessed as secondary outcomes.
Results
The coronary artery diseases requiring PCI were: myocardial infarction (n = 10), unstable angina (n = 10), stable angina (n = 2), and silent ischemia (n = 2). The median interval between PCI and EBUS‐TBNA was 125 days (interquartile range: 66–180). Atrial fibrillation with a rapid ventricular response temporarily occurred in one patient after EBUS‐TBNA. No other significant cardiovascular complications were encountered. Fifteen patients were administered an anti‐thrombotic agent the day of EBUS‐TBNA, while four had ceased taking the agent < 4 days before EBUS‐TBNA, however, there was no significant bleeding among those patients.
Conclusion
EBUS‐TBNA was safe and did not cause serious adverse events in patients with lung cancer who required tissue confirmation or mediastinal staging within one year after PCI. Incidental lung cancer found during or after a coronary intervention should be actively evaluated by EBUS‐TBNA.</description><subject>Aged</subject><subject>Angioplasty</subject><subject>Blood pressure</subject><subject>Bronchoscopy</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Clopidogrel</subject><subject>Coronary vessels</subject><subject>Endoscopic Ultrasound-Guided Fine Needle Aspiration - methods</subject><subject>endoscopic ultrasound‐guided fine needle aspiration</subject><subject>Female</subject><subject>Heart attack</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>lung neoplasm</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>neoplasm staging</subject><subject>Original</subject><subject>Patients</subject><subject>percutaneous coronary intervention</subject><subject>Percutaneous Coronary Intervention - methods</subject><subject>Retrospective Studies</subject><subject>Safety and security measures</subject><subject>Stents</subject><subject>Studies</subject><subject>Tomography</subject><subject>Transluminal angioplasty</subject><subject>Ultrasonic imaging</subject><issn>1759-7706</issn><issn>1759-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqFksFu1DAQQCMEolXpmRuyxIXLbh0ntpML0mpVClIlDpSz5djjXVdZe7GTVnvjE_gEvq1fwmxTthQh4Rxsjd-8yVhTFK9LOi9xnZWStzMpy3pesqYWz4rjQ-T54UzFUXGa8zXFVTUtZfxlcVTRkouqocfFzy_awbAj0REINnYpBrP2uidjPySd4xjs3fcfq9FbsAQjIT8iAcD2QHTe-qQHHwPxgWzxBGHI5NYPa9KPYUWMDgbSfQABTXagE9FuwNgWkhkHHSCOmZiIap12qMG7G7Sg81Xxwuk-w-nDflJ8_XB-tfw4u_x88Wm5uJwZXtViJqhzvIbWAVDBwYhOV6AtpZ1sGGMatOPUdK52jBrJaceZaWRjbFc1QltZnRTvJ-927DZgDVZPulfb5Df4Sypqr57eBL9Wq3ijBKOtlBwF7x4EKX4bIQ9q47OBvp-6U4gJzllZN4i-_Qu9jmMK2J5irG0l-trqkVrpHpQPLmJds5eqhawk5S0rKVLzf1D4Wdh4EwM4j_EnCWdTgkkx5wTu0GNJ1X6u1H5y1H6K1P1cYcabP5_mwP-eIgT4BNxird3_fOpquZjEvwCmW90F</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Gil, Hyun‐Il</creator><creator>Choe, Junsu</creator><creator>Jeong, Byeong‐Ho</creator><creator>Um, Sang‐Won</creator><creator>Jeon, Kyeongman</creator><creator>Hahn, Joo‐Yong</creator><creator>Kim, Hojoong</creator><creator>Kwon, O Jung</creator><creator>Chang, Yoon Soo</creator><creator>Lee, Kyungjong</creator><general>John Wiley & Sons Australia, Ltd</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1642-8111</orcidid></search><sort><creationdate>201811</creationdate><title>Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention</title><author>Gil, Hyun‐Il ; Choe, Junsu ; Jeong, Byeong‐Ho ; Um, Sang‐Won ; Jeon, Kyeongman ; Hahn, Joo‐Yong ; Kim, Hojoong ; Kwon, O Jung ; Chang, Yoon Soo ; Lee, Kyungjong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5346-60ff54e9fee065ec6ba3ead00b78222aeaf50cbf4f20c750b52c878cdb386ad73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Angioplasty</topic><topic>Blood pressure</topic><topic>Bronchoscopy</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Clopidogrel</topic><topic>Coronary vessels</topic><topic>Endoscopic Ultrasound-Guided Fine Needle Aspiration - methods</topic><topic>endoscopic ultrasound‐guided fine needle aspiration</topic><topic>Female</topic><topic>Heart attack</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>lung neoplasm</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>neoplasm staging</topic><topic>Original</topic><topic>Patients</topic><topic>percutaneous coronary intervention</topic><topic>Percutaneous Coronary Intervention - methods</topic><topic>Retrospective Studies</topic><topic>Safety and security measures</topic><topic>Stents</topic><topic>Studies</topic><topic>Tomography</topic><topic>Transluminal angioplasty</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gil, Hyun‐Il</creatorcontrib><creatorcontrib>Choe, Junsu</creatorcontrib><creatorcontrib>Jeong, Byeong‐Ho</creatorcontrib><creatorcontrib>Um, Sang‐Won</creatorcontrib><creatorcontrib>Jeon, Kyeongman</creatorcontrib><creatorcontrib>Hahn, Joo‐Yong</creatorcontrib><creatorcontrib>Kim, Hojoong</creatorcontrib><creatorcontrib>Kwon, O Jung</creatorcontrib><creatorcontrib>Chang, Yoon Soo</creatorcontrib><creatorcontrib>Lee, Kyungjong</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thoracic cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gil, Hyun‐Il</au><au>Choe, Junsu</au><au>Jeong, Byeong‐Ho</au><au>Um, Sang‐Won</au><au>Jeon, Kyeongman</au><au>Hahn, Joo‐Yong</au><au>Kim, Hojoong</au><au>Kwon, O Jung</au><au>Chang, Yoon Soo</au><au>Lee, Kyungjong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention</atitle><jtitle>Thoracic cancer</jtitle><addtitle>Thorac Cancer</addtitle><date>2018-11</date><risdate>2018</risdate><volume>9</volume><issue>11</issue><spage>1390</spage><epage>1397</epage><pages>1390-1397</pages><issn>1759-7706</issn><eissn>1759-7714</eissn><abstract>Background
Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS‐TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS‐TBNA in patients with lung cancer who underwent PCI within one year.
Methods
We retrospectively reviewed the medical records of 24 patients who underwent EBUS‐TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural‐related complications were assessed as secondary outcomes.
Results
The coronary artery diseases requiring PCI were: myocardial infarction (n = 10), unstable angina (n = 10), stable angina (n = 2), and silent ischemia (n = 2). The median interval between PCI and EBUS‐TBNA was 125 days (interquartile range: 66–180). Atrial fibrillation with a rapid ventricular response temporarily occurred in one patient after EBUS‐TBNA. No other significant cardiovascular complications were encountered. Fifteen patients were administered an anti‐thrombotic agent the day of EBUS‐TBNA, while four had ceased taking the agent < 4 days before EBUS‐TBNA, however, there was no significant bleeding among those patients.
Conclusion
EBUS‐TBNA was safe and did not cause serious adverse events in patients with lung cancer who required tissue confirmation or mediastinal staging within one year after PCI. Incidental lung cancer found during or after a coronary intervention should be actively evaluated by EBUS‐TBNA.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>30156380</pmid><doi>10.1111/1759-7714.12846</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1642-8111</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-7706 |
| ispartof | Thoracic cancer, 2018-11, Vol.9 (11), p.1390-1397 |
| issn | 1759-7706 1759-7714 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6209775 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Aged Angioplasty Blood pressure Bronchoscopy Cardiac arrhythmia Cardiology Cardiovascular disease Care and treatment Clopidogrel Coronary vessels Endoscopic Ultrasound-Guided Fine Needle Aspiration - methods endoscopic ultrasound‐guided fine needle aspiration Female Heart attack Heart diseases Humans Lung cancer lung neoplasm Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Lung Neoplasms - surgery Male Middle Aged neoplasm staging Original Patients percutaneous coronary intervention Percutaneous Coronary Intervention - methods Retrospective Studies Safety and security measures Stents Studies Tomography Transluminal angioplasty Ultrasonic imaging |
| title | Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A22%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20endobronchial%20ultrasound%E2%80%90guided%20transbronchial%20needle%20aspiration%20in%20patients%20with%20lung%20cancer%20within%20a%20year%20after%20percutaneous%20coronary%20intervention&rft.jtitle=Thoracic%20cancer&rft.au=Gil,%20Hyun%E2%80%90Il&rft.date=2018-11&rft.volume=9&rft.issue=11&rft.spage=1390&rft.epage=1397&rft.pages=1390-1397&rft.issn=1759-7706&rft.eissn=1759-7714&rft_id=info:doi/10.1111/1759-7714.12846&rft_dat=%3Cgale_pubme%3EA737059210%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299797793&rft_id=info:pmid/30156380&rft_galeid=A737059210&rfr_iscdi=true |